ANI Pharmaceuticals Inc. (ANIP)
ANIP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/0001023024-26-000014-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ANIP on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001023024 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $883.4M |
| Net income | $78.3M |
| Operating income | $111.1M |
| Net margin | 8.9% |
| Operating margin | 12.6% |
| Revenue growth | +43.8% |
| Cash | $285.6M |
| Total assets | $1.4B |
| P/E (computed) | 20.6× |
| P/S (computed) | 1.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $420.8M cash; operating cash flow $57.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 22,729,795 (2026-10-29); 22,469,032 a year earlier. | Cover page 2026-10-29 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | EisnerAmper LLP, Iselin, New Jersey, United States; changed auditors 1 time in 24 months | 8-K 4.01 2026-04-07 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $15.1M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $290.8M | $35.1M | $83.8M | $420.8M | $297.7M | $1.0B | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $266.0M | $24.7M | $56.7M | $360.2M | $301.5M | $978.4M | 10-Q 2026-08-07 |
| Q1 2026 2026-03-31 | $237.5M | $29.5M | $58.4M | $311.2M | $305.3M | $923.7M | 10-Q 2026-05-08 |
| Q4 2025 2025-12-31 | $247.1M | $27.5M | $30.4M | $285.6M | $309.1M | $883.4M | 10-K 2026-02-27 |
| Q3 2025 2025-09-30 | $227.8M | $26.6M | $44.1M | $262.6M | $312.9M | $826.9M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $211.4M | $8.5M | $75.8M | $217.8M | $314.7M | $747.4M | 10-Q 2026-08-07 |
| Q1 2025 2025-03-31 | $197.1M | $15.7M | $35.0M | $149.8M | $316.5M | $674.1M | 10-Q 2026-05-08 |
| Q4 2024 2024-12-31 | $190.6M | -$10.3M | $15.9M | $144.9M | $318.3M | $614.4M | 10-K 2026-02-27 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2023-05-12 |
| Latest annual report | 10-K | 2026-02-27 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEFA14A | 2026-04-09 |
Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +6.0% |
| 1 month | +0.8% |
| 3 months | -4.5% |
| Year to date | -9.5% |
| 1 year | -15.5% |
| From 52-week high | -17.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NRIX | Nurix Therapeutics Inc. | $14.73 | -4.84% | $1.6B |
| RARE | Ultragenyx Pharmaceutical Inc. | $15.90 | -1.12% | $1.6B |
| SRPT | Sarepta Therapeutics Inc. Common Stock (DE) | $15.13 | -5.85% | $1.6B |
| KLRA | Kailera Therapeutics Inc. | $12.57 | -5.28% | $1.6B |
| ADRX | ADARx Pharmaceuticals Inc. | $14.00 | -1.41% | $1.6B |
| PGEN | Precigen Inc. | $4.30 | -5.29% | $1.5B |
| QURE | uniQure N.V. | $21.88 | -8.11% | $1.5B |
| SLS | SELLAS Life Sciences Group Inc. | $7.47 | -4.96% | $1.5B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier